GeoVax Labs to Showcase Vaccine and Immunotherapy Advances at Emerging Growth Conference

GeoVax Labs, Inc., a clinical-stage biotechnology company, is preparing to share significant updates on its vaccine and immunotherapy pipeline at the Emerging Growth Conference on July 16, 2025. The presentation, led by Chairman and CEO David Dodd, will cover the company's advancements in developing the GEO-MVA vaccine for Mpox/smallpox, which has garnered positive feedback from the European Medicines Agency, and the GEO-CM04S1 COVID-19 vaccine, currently undergoing Phase 2 trials. These developments underscore GeoVax's commitment to combating infectious diseases with innovative solutions.

In addition to vaccine progress, Dodd will provide updates on Gedeptin®, a promising therapy for solid tumors, reflecting the company's broader mission to address unmet medical needs across oncology. The presentation will also delve into GeoVax's strategies for diversifying vaccine supply chains and enhancing pandemic readiness, topics of critical importance in the wake of global health crises.

The session, scheduled from 1:10 PM to 1:40 PM Eastern Time, will include a live Q&A, offering stakeholders an opportunity to engage directly with GeoVax's leadership. For those interested in attending, registration is available here, with options to submit questions in advance or during the event. A replay will be accessible on the Emerging Growth website and YouTube channel, ensuring broader access to these insights.

This presentation is a testament to GeoVax Labs' pivotal role in advancing public health through cutting-edge research and development. By focusing on vaccines and immunotherapies for some of the most pressing health challenges, the company is at the forefront of efforts to safeguard global health security.